Capmatinib
Tabrecta, Capmatinib (capmatinib) is a small molecule pharmaceutical. Capmatinib was first approved as Tabrecta on 2008-06-10. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat breast neoplasms. The pharmaceutical is active against hepatocyte growth factor receptor. Tabrecta's patents are valid until 2035-07-22 (FDA).
| Trade Name | Capmatinib |
|---|---|
| Common Name | Capmatinib |
| Indication | breast neoplasms, non-small-cell lung carcinoma |
| Drug Class | Tyrosine kinase inhibitors |
